hMaxi-K has been evaluated in two Phase 1 studies in OAB patients including a small, double-blind, placebo-controlled Phase 1b clinical trial as an intravesical injection in women with overactive

››More information on molar mass and molecular weight. In chemistry, the formula weight is a quantity computed by multiplying the atomic weight (in atomic mass units) of each element in a chemical formula by the number of atoms of that element present in the formula, then adding all … First successful step taken in gene therapy for ED No hMaxi-K was detected in the semen of any of the men at a sensitivity of 1 copy/mg total DNA. Two participants, at the 5,000-and 7,500-μg doses, reported a sustained 100% increase to questions 3 and 4 of the International Index of Erectile Function (dealing with duration and hardness of erection), from 2 to 4. Vivek Ramaswamy's Urovant Files for IPO to Raise $150 Sep 11, 2018

New ED Drugs on Horizon - WebMD

However, the promising primary safety outcomes of the study and preliminary indications of effectiveness provide evidence that hMaxi-K gene transfer is a viable approach to the treatment of ED and that further studies investigating the efficacy of hMaxi-K in patients with ED should be performed. May 24, 2006 · For now, it is called hMaxi-K. Suitably enough for an erection treatment, it is a form of gene therapy called naked DNA. Its DNA carries a human genetic code into target cells. When the cell reads This study is a double-blind, placebo controlled, parallel design, Phase 2A study evaluating the potential activity and safety of a single administration of hMaxi-K (8000 or 16000 µg) or placebo (PBS sucrose 20%) injected into the corpus cavernosum of the penis in men who have been unable to tolerate, do not wish to continue, or have had unsuccessful results with, prior therapy for ED.

hMaxi-K has been evaluated in two Phase 1 studies in OAB patients including a small, double-blind, placebo-controlled Phase 1b clinical trial as an intravesical injection in women with overactive

However, the promising primary safety outcomes of the study and preliminary indications of effectiveness provide evidence that hMaxi-K gene transfer is a … Phase 2A Clinical Trial Evaluating the Potential Activity This study is a double-blind, placebo controlled, parallel design, Phase 2A study evaluating the potential activity and safety of a single administration of hMaxi-K (8000 or 16000 g) or placebo (PBS sucrose 20%) injected into the corpus cavernosum of the penis in men who have been unable to tolerate, do not wish to continue, or have had unsuccessful results with, prior therapy for ED. Urovant licenses overactive bladder gene therapy hMaxi-K